AAPLLoadingMSFTLoadingNVDALoadingGOOGLLoadingAMZNLoadingMETALoadingTSLALoadingAMDLoadingNFLXLoadingCOINLoadingPYPLLoadingSPYLoadingQQQLoadingIWMLoadingJPMLoadingVLoadingDISLoadingKOLoadingJNJLoadingNKELoadingXOMLoadingASMLLoading
FreeLLY3 min read

Manufacturing capacity is the constraint people keep forgetting

It traded at 1157.28 this morning, +0.97% on the session. There is a category of investment problem where the demand question is settled and the interesting question is entirely industrial.

LLY
Delayed

When supply is the binding constraint

Normally a pharmaceutical forecast is a demand forecast: how many patients, what share, what price. When production cannot meet demand, all of that becomes irrelevant. Revenue is whatever can be manufactured, and the forecast is a construction timetable.

That is an unusual position and it changes what is worth reading. The clinical data matters less than it did, because it has already done its job. The capacity announcements matter enormously and read like operations news rather than investment news.

What I track

  • Announced capacity expansions and, more importantly, their commissioning dates
  • Fill-finish capacity specifically, which has been the bottleneck more often than the active ingredient
  • Contract manufacturing arrangements, which add capacity faster than building does
  • Any disclosure about supply meeting demand, which is the signal that the constraint is lifting

Where I stand

Long, on the straightforward basis that capacity is being added against demand that exists today. That is a considerably more knowable proposition than most things in this sector.

When you cannot make enough of it, the marketing department is not the interesting one. The engineers are.

Where I would be wrong

If capacity arrives faster than demand persists. Supply constraints end, and they can end abruptly when several expansions commission at once. The company that could not make enough becomes the company with a large fixed cost base and a demand question after all.

The signal would be capacity commissioning ahead of schedule while prescription growth flattens. That combination is the one to watch, and it would arrive before any change in the reported revenue.

The author holds no position in the instruments discussed. Opinion. Not advice. Not a financial promotion approved under FSMA s.21. Quote data is delayed. Past performance is not a reliable indicator of future results.

Comments

0 comments
Sign in to comment.

No comments yet

Be the first to weigh in.